Calcipotriene

For the treatment of Plaque Psoriasis, the standard adult dosage for calcipotriene (ointment, cream, or scalp solution) is a thin layer applied to the affected skin areas twice daily (once in the morning and once in the evening). Some patients may find that once-daily application is sufficient for maintenance after initial improvement.

Maximum Dosage Limit: It is clinically critical that adults do not exceed 100 grams per week of the cream or ointment. For the scalp solution, the limit is typically 60 mL per week. Exceeding these limits significantly increases the risk of systemic absorption, which can lead to elevated blood calcium levels (hypercalcemia), a potentially serious condition.

Calcipotriene use in children must be strictly supervised by a pediatric dermatologist.

• Children (12-17 years): The ointment or cream may be applied twice daily. The maximum weekly dose should not exceed 75 grams.
• Children (6-11 years): The maximum weekly dose should not exceed 50 grams.
• Children under 6 years: Safety and efficacy have not been established; use is generally not recommended in this age group unless specifically directed by a specialist.

Renal Impairment

Patients with known kidney disease should use calcipotriene with extreme caution. Since the kidneys are responsible for calcium homeostasis (balance), any systemic absorption of calcipotriene could exacerbate underlying mineral imbalances. Dose reduction or more frequent monitoring of serum calcium may be required.

Hepatic Impairment

Because calcipotriene is primarily metabolized in the liver, patients with severe hepatic impairment may have a reduced ability to clear the drug if it is absorbed systemically. While topical use is generally safe, healthcare providers may limit the total surface area treated to prevent accumulation.

Elderly Patients

Clinical studies have not identified significant differences in response between elderly and younger patients. However, because older adults are more likely to have reduced renal function or be taking other medications that affect calcium (like thiazide diuretics), a conservative approach to the total weekly dose is often recommended.

To ensure the best results and minimize side effects, follow these application steps:

1. 1Clean the Area: Gently wash and dry the affected skin before application.
2. 2Apply a Thin Layer: Use only enough medication to cover the psoriatic plaque. Do not 'slather' the medication on; more is not better and increases the risk of irritation.
3. 3Rub in Gently: Massage the cream or ointment into the skin until it disappears.
4. 4Wash Hands: Immediately wash your hands after application unless your hands are the area being treated. This prevents accidental transfer to sensitive areas like the face or eyes.
5. 5Avoid Sensitive Areas: Do not apply to the face, skin folds (axilla/groin), or genitals unless specifically instructed, as these areas are more prone to irritation.
6. 6Storage: Store at room temperature (68°F to 77°F). Do not freeze. Keep the tube or bottle tightly closed.

If you miss a dose, apply it as soon as you remember. However, if it is almost time for your next scheduled application, skip the missed dose and return to your regular routine. Do not apply double the amount to make up for a missed dose, as this increases the risk of localized skin irritation.

An overdose of topical calcipotriene usually occurs through chronic over-application (exceeding the 100g/week limit) rather than a single large application.

• Signs of Chronic Overdose: These are symptoms of hypercalcemia, including persistent nausea, vomiting, constipation, extreme thirst, frequent urination, muscle weakness, and confusion.
• Emergency Measures: If you suspect you have used too much or if a child has accidentally swallowed the medication, contact a Poison Control Center or seek emergency medical care immediately. Treatment usually involves discontinuing the drug until calcium levels return to normal.

> Important: Follow your healthcare provider's dosing instructions exactly. Do not adjust your dose or apply it to larger areas of your body without medical guidance.

Most patients tolerate calcipotriene well, but localized skin reactions are the most frequent complaints. These typically occur shortly after application and may diminish as the skin adjusts to the treatment.

• Burning and Stinging: A transient (temporary) sensation of heat or sharp stinging at the application site. This usually lasts for 5-15 minutes.
• Skin Irritation (Pruritus): Itching of the treated skin. This can range from a mild tickle to a more intense urge to scratch.
• Dryness and Erythema: Redness (erythema) and a feeling of tightness or dryness in the skin surrounding the psoriasis plaque.

• Dermatitis: Inflammation of the skin that may look like a rash or small red bumps.
• Exacerbation of Psoriasis: In some cases, the medication may cause the psoriasis to temporarily look worse or spread slightly before improvement begins.
• Skin Peeling (Desquamation): Flaking of the skin, which is often a sign of the medication working to shed the excess keratinocytes, though it can be bothersome.
• Photosensitivity: Increased sensitivity to sunlight. The treated skin may burn more easily when exposed to UV rays.

• Hyperpigmentation or Hypopigmentation: Temporary darkening or lightening of the skin at the site of application.
• Folliculitis: Inflammation of the hair follicles, appearing as small pimples around the hair shafts.
• Atrophy: While much less common than with steroids, very prolonged use on thin skin may lead to slight thinning of the skin barrier.

While rare when used correctly, systemic absorption can lead to serious metabolic issues.

> Warning: Stop taking Calcipotriene and call your doctor immediately if you experience any of these:

• Hypercalcemia Symptoms: This is the most serious potential complication. Watch for extreme fatigue, 'brain fog' or confusion, severe bone or joint pain, and cardiac arrhythmias (irregular heartbeat). This occurs when the drug affects the body's internal calcium balance.
• Severe Allergic Reaction (Anaphylaxis): Symptoms include hives, difficulty breathing, swelling of the face, lips, tongue, or throat. This is a medical emergency.
• Severe Skin Blistering: If the medication causes the skin to blister or weep, it may indicate a severe contact dermatitis or chemical burn.
• Facial Swelling: Edema (swelling) of the face, even if the medication was not applied there, can occur in rare systemic reactions.

The long-term safety of calcipotriene has been studied for up to one year in continuous use.

• Tachyphylaxis: Unlike topical steroids, calcipotriene does not typically exhibit 'tachyphylaxis' (where the drug loses effectiveness over time). It remains effective for long-term maintenance.
• Calcium Metabolism: Long-term use over large surface areas requires periodic monitoring of serum calcium to ensure that the cumulative absorption does not lead to 'silent' hypercalciuria (excess calcium in the urine), which can contribute to kidney stones.
• Skin Texture: Prolonged use is generally safer for the skin's structural integrity than steroids, making it a preferred choice for long-term management of chronic plaques.

No FDA black box warnings are currently issued for calcipotriene. It is considered a safe and effective medication when used within the prescribed dosage limits (under 100g/week for adults).

Report any unusual symptoms or persistent skin changes to your healthcare provider to ensure your treatment plan remains safe and effective.

Calcipotriene is for external use only. It must not be used in the eyes, mouth, or vagina. If the medication accidentally comes into contact with the eyes, it can cause severe irritation; rinse thoroughly with cool water immediately. Patients should be aware that calcipotriene is a potent metabolic agent; while it is applied to the skin, its effects can become systemic if the skin barrier is broken or if excessive amounts are used.

There are no FDA black box warnings for Calcipotriene. It has a well-established safety profile spanning over three decades of clinical use.

• Hypercalcemia and Hypercalciuria: The most significant risk associated with calcipotriene is the elevation of serum calcium levels. This is strictly dose-dependent. If you have a pre-existing disorder of calcium metabolism, you must inform your doctor.
• UV Exposure: Calcipotriene can be degraded by light and may also make your skin more sensitive to the sun. Patients undergoing phototherapy (PUVA or UVB) should apply calcipotriene after their light treatment, not before. Limit sun exposure and use protective clothing on treated areas.
• Facial and Intertriginous Use: The skin on the face and in skin folds (like the armpits or under the breasts) is much thinner and more sensitive. Calcipotriene is not typically recommended for these areas as it can cause severe 'burning' and irritant dermatitis.
• Allergic Contact Dermatitis: Some patients may develop an allergy to the active ingredient or the preservatives in the cream/ointment (such as propylene glycol). If a rash spreads beyond the treatment area, consult your dermatologist.

For most patients using standard amounts, routine blood work is not necessary. However, your healthcare provider may require monitoring in the following scenarios:

• Large Area Treatment: If you are treating more than 20% of your body surface area.
• High Dose Use: If you are consistently approaching the 100g/week limit.
• Pre-existing Conditions: If you have underlying renal insufficiency or bone disease.
• Tests: The primary tests involve measuring Serum Calcium, Albumin, and sometimes Urinary Calcium to ensure the drug is not affecting your mineral balance.

Calcipotriene is a topical medication with no known sedative or psychoactive effects. It does not impair the ability to drive or operate heavy machinery.

There are no direct chemical interactions between topical calcipotriene and alcohol. However, alcohol consumption is a known trigger for psoriasis flares in many individuals. Excessive drinking may reduce the overall efficacy of your psoriasis management plan.

One of the benefits of calcipotriene compared to topical steroids is that it does not typically cause a 'rebound' effect (where the disease returns significantly worse than before) when stopped. However, you should not stop treatment abruptly without consulting your doctor, as a gradual transition to a maintenance therapy may be better for long-term clearance.

> Important: Discuss all your medical conditions, especially any history of kidney stones or high calcium, with your healthcare provider before starting Calcipotriene.

There are no medications that are absolutely contraindicated for use with calcipotriene, provided it is used topically and within dosage limits. However, it should not be used simultaneously with other potent Vitamin D analogs (like oral Calcitriol) unless under the strict supervision of a specialist, as this significantly compounds the risk of systemic Vitamin D toxicity.

• Thiazide Diuretics (e.g., Hydrochlorothiazide): These 'water pills' can reduce the amount of calcium excreted by the kidneys. If calcipotriene is absorbed systemically while a patient is on a thiazide, the risk of developing hypercalcemia is significantly increased.
• Calcium Supplements: High doses of oral calcium (greater than 1000mg/day) can synergize with absorbed calcipotriene to raise blood calcium levels.
• Vitamin D Supplements: Taking high-dose oral Vitamin D (ergocalciferol or cholecalciferol) while using calcipotriene can lead to additive effects on calcium absorption from the gut and bone.

• Topical Corticosteroids: This is a common and often beneficial interaction. Doctors frequently prescribe these together because they work via different mechanisms. However, they should generally not be mixed in the same palm before application unless using a pre-formulated combination product (like Taclonex), as the pH of one may degrade the other.
• Salicylic Acid: Topical preparations containing salicylic acid (often used to 'de-scale' psoriasis) can inactivate calcipotriene. If both are prescribed, they should be applied at different times of the day (e.g., salicylic acid in the morning, calcipotriene in the evening).

• High Calcium Diet: While normal dietary intake of dairy is fine, extremely high intake of calcium-fortified foods combined with excessive calcipotriene use could theoretically impact serum levels.
• Grapefruit: Unlike many oral medications, topical calcipotriene is not significantly affected by grapefruit juice consumption because it bypasses the initial 'first-pass' metabolism in the gut.

• St. John's Wort: While St. John's Wort induces CYP3A4 enzymes (which metabolize many drugs), the systemic levels of calcipotriene are usually too low for this to be a major clinical concern.
• Multivitamins: Patients should check the Vitamin D content of their multivitamins to ensure they are not exceeding the recommended daily allowance while using calcipotriene over large areas.

Calcipotriene does not typically interfere with standard laboratory assays (like glucose or cholesterol tests). However, its systemic absorption can directly alter the results of:

• Serum Calcium: May show false elevations if the drug is overused.
• Parathyroid Hormone (PTH): Systemic Vitamin D analogs can suppress PTH levels as the body tries to compensate for perceived high calcium.

For each major interaction, the mechanism is usually related to pharmacodynamic synergy—where two substances have the same effect on the body (in this case, raising calcium)—rather than a chemical interference. The management strategy is typically to monitor blood levels or adjust the timing of application.

> Important: Tell your doctor about ALL medications, supplements, and herbal products you are taking, including those you only use occasionally.

Calcipotriene must NEVER be used in the following circumstances:

• Known Hypersensitivity: If you have had an allergic reaction (rash, hives, swelling) to calcipotriene or any ingredient in the cream, ointment, or solution.
• Pre-existing Hypercalcemia: Patients who already have high levels of calcium in their blood (due to hyperparathyroidism, sarcoidosis, or bone metastases) must not use this drug. Adding a Vitamin D analog could push calcium levels into a range that causes kidney damage or heart rhythm issues.
• Vitamin D Toxicity: If a patient is already suffering from the effects of excessive Vitamin D levels.

These conditions require a careful risk-benefit analysis by a physician:

• Acute Eruptive Psoriasis: In cases of 'guttate' or 'pustular' psoriasis where the skin is highly inflamed and broken, the risk of excessive absorption and severe irritation is much higher.
• Renal Calculi (Kidney Stones): Patients with a history of calcium oxalate stones should use calcipotriene cautiously, as even a slight increase in urinary calcium (hypercalciuria) can trigger new stone formation.
• Facial Psoriasis: Due to the high risk of irritant dermatitis, calcipotriene is generally avoided on the face unless used in very specific, low-frequency regimens under a doctor's eye.

There is a potential for cross-sensitivity with other Vitamin D analogs such as Calcitriol or Maxacalcitol. If you have reacted poorly to one form of topical Vitamin D, you are likely to react to others. However, there is no cross-sensitivity between calcipotriene and topical corticosteroids or coal tar treatments.

> Important: Your healthcare provider will evaluate your complete medical history, including any history of bone disease or mineral imbalances, before prescribing Calcipotriene.

Calcipotriene is classified as Pregnancy Category C under the older FDA system. This means that animal reproduction studies have shown an adverse effect on the fetus (often related to skeletal variations when high doses were given orally), but there are no adequate and well-controlled studies in humans.

• Trimester-Specific Risks: There is no evidence of a specific 'window' of danger, but systemic absorption should be minimized.
• Clinical Guidance: Calcipotriene should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus. Most dermatologists recommend limiting the treated area to less than 10% of the body surface to minimize any possible systemic exposure.

It is not known whether topical calcipotriene is excreted in human milk. Because many drugs are excreted in milk, caution should be exercised.

• Safety Tip: To prevent the infant from accidentally ingesting the drug or coming into contact with it, mothers should not apply calcipotriene to the chest or nipples before breastfeeding. Always wash hands thoroughly before holding the baby.

Calcipotriene is FDA-approved for use in children (specifically the ointment and cream for ages 12 and up, though some formulations have data for younger children).

• Growth Effects: Long-term studies have not shown that topical calcipotriene affects growth or bone development in children, provided the weekly dose limits (50g-75g depending on age) are strictly followed.
• Irritation: Children often have thinner skin than adults and may experience more frequent burning or stinging sensations.

In clinical trials, no overall differences in safety or effectiveness were observed between subjects over 65 and younger subjects.

• Pharmacokinetic Changes: While skin absorption doesn't change significantly with age, elderly patients are more likely to have decreased renal function. This makes them more susceptible to hypercalcemia if the drug is overused.
• Polypharmacy: Older adults are often on multiple medications (like Digoxin or diuretics) that can interact with calcium levels, necessitating closer supervision.

Patients with a GFR (Glomerular Filtration Rate) below 60 mL/min should be monitored closely. The kidneys are the primary regulators of calcium and phosphate; if calcipotriene absorption occurs, a compromised kidney may not be able to compensate, leading to rapid onset of hypercalcemia.

While topical absorption is low, the liver is the site of calcipotriene metabolism. Patients with Child-Pugh Class C (severe) cirrhosis should be treated with the smallest effective dose over the smallest possible area to prevent any systemic accumulation of the drug.

> Important: Special populations require individualized medical assessment and often more frequent follow-up appointments to ensure the medication is working safely.

Calcipotriene is a synthetic Vitamin D3 analog that acts as a high-affinity ligand for the Vitamin D Receptor (VDR). Once it binds to the VDR in the cytoplasm of skin cells, the receptor-ligand complex translocates to the nucleus. There, it binds to Vitamin D Response Elements (VDRE) on specific genes.

This genetic 'switching' results in:

1. 1Inhibition of Proliferation: It downregulates the expression of genes responsible for the rapid cell cycle of keratinocytes (specifically inhibiting the transition from the G1 to the S phase).
2. 2Induction of Differentiation: It increases the expression of markers for mature skin cells, such as involucrin and transglutaminase, which are necessary for a functional skin barrier.
3. 3Immunomodulation: It suppresses the production of pro-inflammatory cytokines like IL-2, IFN-gamma, and IL-17, which are the primary drivers of the psoriatic 'vicious cycle'.

• Onset of Action: Improvement in scaling is often seen within 2 weeks, while redness and plaque thickness may take 4 to 8 weeks to show significant reduction.
• Duration of Effect: The effects on cell turnover persist as long as the medication is applied. If discontinued, the skin's cell cycle will gradually return to its baseline state over several weeks.
• Tolerance: There is no evidence of pharmacological tolerance; the drug remains effective over years of intermittent use.

| Parameter | Value |

|---|---|

| Bioavailability | <6% (Topical, intact skin) |

| Protein Binding | Approx. 95% (to Vitamin D Binding Protein) |

| Half-life | 2-5 hours (systemic fraction) |

| Tmax | Not applicable for topical; systemic peak within 8-12 hours of large-scale application |

| Metabolism | Hepatic (CYP-mediated side-chain oxidation) |

| Excretion | Fecal (Major), Renal (Minor, ~15%) |

• Molecular Formula: C27H40O3
• Molecular Weight: 412.6 g/mol
• Solubility: Practically insoluble in water; soluble in alcohol and fatty oils.
• Structure: It features the classic secosteroid backbone of Vitamin D but with a unique chemically modified side chain (containing a cyclopropane ring) that allows for rapid metabolic inactivation.

Calcipotriene is a Vitamin D Analog. Within the therapeutic area of dermatology, it is grouped with other non-steroidal anti-psoriatic agents. It is often compared to topical retinoids (like tazarotene) and calcineurin inhibitors (like tacrolimus), though its mechanism is distinctively focused on Vitamin D pathways.